November 01, 2014 12:50 AM ET

Biotechnology

Company Overview of Civitas Therapeutics, Inc.

Company Overview

Civitas Therapeutics, Inc., a biopharmaceutical company, develops and commercializes transformative therapeutics using its ARCUS technology. Its technology enables the delivery of a precise dose to the lung to potentially enable rapid and predictable L-dopa absorption through a reusable, pocket-size, and breath-actuated inhaler. The company offers CVT-301, a inhaled L-dopa therapy for OFF episodes that provides rapid delivery of L-dopa to the brain to be used in conjunction with a Parkinson’s disease patient’s individually optimized oral L-dopa regimen. Civitas Therapeutics, Inc. was formerly known as Corregidor Therapeutics, Inc. and changed its name to Civitas Therapeutics, Inc. in April 2...

190 Everett Avenue

Chelsea, MA 02150

United States

Founded in 2009

44 Employees

Phone:

617-660-4110

Fax:

617-884-3990

Key Executives for Civitas Therapeutics, Inc.

Chief Executive Officer
Age: 47
Co-Founder
Age: 52
Co-Founder and Chief Scientific Officer
Age: 46
Co-Founder and Chief Medical Officer
Age: 53
Co-Founder and Chairman of Scientific & Clinical Advisory Board
Age: 66
Compensation as of Fiscal Year 2014.

Civitas Therapeutics, Inc. Key Developments

Acorda Therapeutics, Inc., Civitas Therapeutics, Inc. - M&A Call

To discuss entry of Acorda Therapeutics into an agreement to acquire Civitas Therapeutics

Civitas Therapeutics, Inc. Presents at Boston CEO Conference, Jun-04-2014 03:00 PM

Civitas Therapeutics, Inc. Presents at Boston CEO Conference, Jun-04-2014 03:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Glenn V. Batchelder, Co-Founder and Director.

Civitas Therapeutics, Inc. Announces Positive Results from A Phase 2B Clinical Trial of CVT-301

Civitas Therapeutics, Inc. announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa). Study results from Phase 2 studies will be presented at the 66th Annual American Academy of Neurology Meeting on April 29, 2014 at 2:30pm ET in Philadelphia, PA. CVT-301 is being developed as an adjunctive, as-needed therapy to provide rapid and reliable relief from intermittent debilitating motor fluctuations, known as OFF episodes, suffered by Parkinson's disease patients. OFF episodes, which result from the unpredictable nature of oral baseline therapies, affect over half of all patients on an oral L-dopa treatment regimen and are considered to be one of the most important issues facing Parkinson's disease patients. The Phase 2b study was designed to assess the on-demand use of CVT-301 in Parkinson's disease patients experiencing motor fluctuations over a one-month period. The trial evaluated the efficacy, safety and tolerability of two doses of CVT-301. Motor responses were evaluated during regularly-scheduled clinical visits using the Unified Parkinson's Disease Rating Scale Part 3 (UPDRS III). In addition, efficacy was also evaluated during out-patient use with commonly used diary-based outcomes measures. The primary endpoint was successfully met with CVT-301 achieving a clinically important and statistically significant reduction in average UPDRS III motor score versus placebo at time points ranging from 10 to 60 minutes post-administration (p < 0.001). Furthermore, clinically important and statistically significant improvements in UPDRS III were seen at every time point including 10 minutes, the earliest time point tested, for both tested doses. Over the course of the study, patients self-administered CVT-301 as-needed to treat approximately 4,500 OFF episodes, at an average of approximately 2 treatments per day. With self-administration during at-home use, CVT-301 use was not associated with any increase in either non-troublesome or troublesome dyskinesia. All doses of CVT-301 were safe and well-tolerated, and the CVT-301 inhaler was also shown to be easily utilized by Parkinson's disease patients in the OFF state.

Similar Private Companies By Industry

Company Name Region
FermaVir Pharmaceuticals, L.L.C. United States
Triton Algae Innovations Ltd. United States
AntiCancer, Inc. United States
Calistoga Pharmaceuticals, Inc. United States
Golden West Biologicals, Inc United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 24, 2014
--
Private Placement
August 22, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Civitas Therapeutics, Inc., please visit www.civitastherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.